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Background.TheratioofCA-MRSAinchildrenwithimpetigohasbeenincreasinginJapan.Methods.Antimicrobialsusceptibilities
of 136 S. aureus isolates from children with impetigo were studied. Furthermore, molecular epidemiological analysis and virulence
gene analysis were performed. Results. Of the 136 S. aureus isolates, 122 (89.7%) were MSSA and 14 (10.3%) were MRSA. Of the
14 MRSA strains, 11 belonged to CC89 (ST89, ST91, and ST2117) and carried diverse types of SCCmec: type II (IIb: 3 strains;
unknown subtype: 4 strains), type IVa (2 strains), and unknown type (2 strains). The remaining three strains exhibited CC8
(ST-8)-SCCmec type VIa, CC121 (ST121)-SCCmec type V, and CC5 (ST5)-nontypeable SCCmec element, respectively. None were
lukS-PV-lukF-PVgenepositive.Gentamicin-andclarithromycin-resistantstrainswerefrequentlyfoundinbothMRSAandMSSA.
Conclusions.PVL-negativeCC89-SCCmectypeIIstrainsarethemostpredominantstrainsamongtheCA-MRSAstrainscirculating
in the community in Japan.
1.Introduction
Staphylococcus aureus (S. aureus)i sa ne t i o l o g i ca g e n tf o ra
wide range of illnesses from localized skin infections such as
impetigo, furuncles, and cellulitis to life-threatening diseases
such as pneumonia, meningitis, osteomyelitis, necrotizing
fasciitis, endocarditis, toxic shock syndrome, and bacteremia
[1]. Hospital-associated methicillin-resistant S. aureus (HA-
MRSA) ﬁrst appeared in 1961 shortly after the introduction
of methicillin under the selective pressure of antibiotics
[2,3]. Since then, numerous MRSA clones have emerged and
become a major cause of nosocomial infections throughout
the world [4–6]. MRSA produces penicillin-binding protein
2  (PBP2 )wi t hal o wa ﬃnity for β-lactam antibiotics. PBP2 
is encoded by the mecA gene, which is located on a large
mobile genetic DNA element, the staphylococcal cassette
chromosome mec (SCCmec)[ 7, 8]. Early MRSA clones
were HA-MRSA isolated from patients with compromised
immune systems under medical procedures. However, in
1993,community-associatedMRSA(CA-MRSA)emergedin
patients without risk factors in Western Australia [9]. CA-
MRSA clones, which are distinct from HA-MRSA clones,
have evolved diﬀerently in separate geographical areas and
havespreadincommunities[10].Theincidenceofinfections
due to CA-MRSA, including infections in children with
no identiﬁable risk factors, has increased worldwide as a
community pathogen [11, 12]. There are several types of
CA-MRSA clones including ST1 (USA400) in Asia, Europe,
and the US, ST8 (USA 300) in Europe and the US, ST30
in Australia, Europe, and South America, ST59 in Asia and
the US, and ST80 (European clone) in Asia, Europe, and the
Middle East. However, recent studies have shown that CA-
MRSA strains are spreading into hospitals and are replacing2 International Journal of Pediatrics
traditional HA-MRSA strains [13, 14]. Therefore, distinction
between the traditional HA-MRSA and CA-MRSA strains
based on epidemiologic deﬁnitions has become diﬃcult, and
distinction based on the molecular typing is unclear [4, 15].
S. aureus is both a commensal organism and a pathogen.
S. aureus colonized in the anterior nares, skin, and gas-
trointestinal tract plays an important role in transmission
among individuals and in development of infection [16].
Hisata et al. and Ozaki et al. reported that the prevalences
of nasal carriage of S. aureus in healthy Japanese children
were 28.2% and 40.4%, respectively, and that the ratios of
MRSA strains among the S. aureus isolates were 15.1% and
9.1%, respectively [17, 18]. Impetigo is a highly contagious
infection of the superﬁcial epidermis and is commonly
caused by exfoliative toxins (ETs) of S. aureus [19]. The
ratio of MRSA among S. aureus isolates from patients with
impetigo between 1994 and 2000 was below 20% in Japan
[20]. However, the ratio of MRSA has recently increased to
20 ∼ 50% in Japan [21–24].
The characteristics of CA-MRSA strains in Japan are
diﬀerent from those reported in other countries. Although
highly virulent CA-MRSA strains carrying Panton-Valentine
leukocidin (PVL) genes have been spreading widely in the
world, PVL-negative CA-MRSA has been disseminated in
Japan [15, 17, 18, 23, 25] .T h ea i mo ft h i ss t u d yw a st oi n v e s -
tigate the molecular epidemiology by multilocus sequence
typing(MLST)andstaphylococcalcassettechromosomemec
(SCCmec) typing and the antimicrobial susceptibilities of
S. aureus isolates from children with impetigo.
2.MaterialsandMethods
2.1. Bacterial Strains. Samples were isolated from skin swabs
taken from pediatric outpatients with impetigo. A total of
136 S. aureus isolates were collected from 136 diﬀerent
patients (69 males and 67 females; mean age: 3.8 years; SD:
2.3 years) with impetigo at private oﬃces of 25 practicing
pediatricians and 10 hospitals between June 2009 and June
2010 in Hokkaido, the northernmost island of Japan. All
samples were collected after obtaining informed consent
from the children’s parents. MRSA strains were identiﬁed by
polymerase chain reaction (PCR) for the mecA gene and by
the detection of penicillin-binding protein 2  (Denka Seiken,
Co., Tokyo, Japan).
2.2. Molecular Typing and Virulence Gene Analysis. PCR
primers used for molecular typing and virulence gene
analysis in this study are listed in Table 1.T h ep r e s e n c e
of genes encoding PVL (lukS-PV-lukF-PV), toxic shock
syndrome toxin 1 (TSST-1) (tst), and 2 ETs (ETA, ETB)
(eta, etb) was examined by the PCR method using previously
reported primers [26]. MRSA isolates were characterized by
MLST as speciﬁc sequence types (STs) and clonal complexes
(CCs) based on the DNA sequences at 7 deﬁned loci. MLST
was performed as described by Enright et al. [27]. MLST
is based on sequence analysis of PCR products from seven
S. aureus housekeeping genes, that is, arcC, aroE, glpF, gmk,
pta, tpi, and yqiL. Each sequence was submitted to the MLST
database website (http://www.mlst.net/) for the assignment
of the allelic proﬁle and ST. Diﬀerent sequences are assigned
distinct alleles of each housekeeping gene, and each isolate
is deﬁned by alleles of the seven genes. The ST data were
further analyzed using eBURST (http://eburst.mlst.net/)t o
determine the CC. SCCmec typing was performed by the
multiplex PCR method described by Kondo et al. SCCmec
types (I to VI) were determined on the basis of the class
(classes A, B, and C) of mec gene complex and the type
(types 1, 2, 3, 4, and 5) of ccr gene complex [26]. Subtyping
of SCCmec types II and IV was performed on the basis of
diﬀerent J1 regions by PCR using published primers [28].
2.3. Antimicrobial Susceptibility Testing. For in vitro antimi-
crobial susceptibility testing, minimal inhibitory concentra-
tions (MICs) of a panel of 12 antimicrobial drugs, that
is, oxacillin (MPIPC), ampicillin (ABPC), cefaclor (CCL),
cefditoren (CDTR), clarithromycin (CAM), clindamycin
(CLDM), fosfomycin (FOM), minocycline (MINO), gen-
tamicin (GM), vancomycin (VCM), nadiﬂoxacin (NDFX),
and fucidic acid (FA), were determined using a frozen plate
(Eiken Chemical Co., Tokyo, Japan). This plate is based on
the broth microdilution method recommended by the Japan
Society for Chemotherapy (JSC) [29, 30]. The breakpoints
for these antimicrobial agents were determined according
to the interpretation criteria of Clinical and Laboratory
Standards Institute (CLSI) [31, 32]a n dJ S C[ 29, 30]. Sus-
ceptibilities to antimicrobial drugs for which breakpoints are
notdeterminedbyCLSIandJSCweredeﬁnedinthisstudy.A
nitroceﬁn method was used for β-lactamase detection [33].
3. Results
In the bacteriological analysis of the 155 patients with
impetigo, S. aureus and Streptococcus pyogenes were isolated
from 136 and 6, respectively. Two cases involved two
pathogens. No pathogenic organism was isolated from 15
patients. Of the 136 S. aureus cases, 122 (89.7%) were MSSA
and 14 (10.3%) were MRSA. The 14 MRSA patients except
for two newborns did not have a history of hospitalization
during the previous year. Age distribution in the 136 patients
was shown in Table 2.
The molecular characteristics of the 14 MRSA strains
isolated from the patients with impetigo were examined and
aresummarizedinTable 3.Amongthe14strainsthatcarried
the mec gene complex, 11 were determined the SCCmec
element type. By SCCmec typing, the 14 MRSA strains were
deﬁned as SCCmec type II (IIb: 3 strains; IINT: 4 strains),
type IVa (3 strains), type V (1 strain), and unknown type
(3 strains). Types of ccr gene complex in 3 strains could not
be determined.
The 14 MRSA strains were comprised of 4 CCs. The
four CCs were CC89 (11/14), CC5 (1/14), CC8 (1/14), and
CC121 (1/14). ST89, ST91, and ST2117 strains belonged to
the same CC89. No PVL-positive strains were identiﬁed in
the 14 MRSA strains. The MRSA strains belonging to ST5
and ST8 carried TSST-1. Of the 14 MRSAstrains, 11 (78.6%)
were etb gene positive, and one was eta gene positive. ThereInternational Journal of Pediatrics 3
Table 1 :L i s to fp r i m e r s .
Gene Primer name Size of product (bp) Primer sequence (5  →3 ) Reference
(1) Detection of virulence gene [26]
lukS-PV-lukF-PV luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA
luk-PV-2 433 GCATCAASTGTATTGGATAGCAAAAGC
tst TST-1 TTCACTATTTGTAAAAGTGTCAGACCCACT
TST-2 180 TACTAATGAATTTTTTTATCGTAAGCCCTT
eta mpETA-1 ACTGTAGGAGCTAGTGCATTTGT
mpETA-3 190 TGGATACTTTTGTCTATCTTTTTCATCAAC
etb mpETB-1 CAGATAAAGAGCTTTATACACACATTAC
mpETB-2 621 AGTGAACTTATCTTTCTATTGAAAAACACTC
(2) SCCmec typing [28]
(i) ccr gene complex type with mecA
mecA mA1 TGCTATCCACCCTCAAACAGG
mA2 286 AACGTTGTAACCACCCCAAGA
Type 1 α1 AACCTATATCATCAATCAGTACGT
βc 695 ATTGCCTTGATAATAGCCITCT
Type 2 α2 TAAAGGCATCAATGCACAAACACT
βc 937 ATTGCCTTGATAATAGCCITCT
Type 3 α3 AGCTCAAAAGCAAGCAATAGAAT
βc 1,791 ATTGCCTTGATAATAGCCITCT
Type 4 α4.2 GTATCAATGCACCAGAACTT
β4.2 1,287 TTGCGACTCTCTTGGCGTTT
type 5 γF CGTCTATTACAAGATGTTAAGGATAAT
γR 518 CCTTTATAGACTGGATTATTCAAAATAT
(ii) mec gene complex class
mecA ml6 CATAACTTCCCATTCTGCAGATG
mA7 1,963 ATATACCAAACCCGACAACTACA
mecB IS7 ATGCTTAATGATAGCATCCGAATG
mA7 2,827 ATATACCAAACCCGACAACTACA
mecC (C2) mA7 ATATACCAAACCCGACAACTACA
IS2(iS-2) 804 TGAGGTTATTCAGATATTTCGATGT
(iii) SCCmec type II subtyping
IIa (II.1) kdpB2 TAAACTGTGTCACACGATCCAT
kdpB1 287 GATTACTTCAGAACCAGGTCAT
IIb (II.2) 2b3 GCTCTAAAAGTTGGATATGCG
2b4 1,518 TGGATTGAATCGACTAGAATCG
IIE (II.3) 4b3 AACCAACAGTGGTTACAGCTT
4b4 726 CGGATTTTAGACTCATCACCAT
II.4 II4-3 GTACCGCTGAATATTGATAGTGAT
II4-1 2,003 ACTCTAATCCTAATCACCGAAC
(iv) SCCmec type IV subtyping
IVa (IV.1) 4al TTTGAATGCCCTCCATGAATAAAAT
4a3 458 AGAAAAGATAGAAGTTCGAAAGA
IVb (IV.2) 4b3 AACCAACAGTGGTTACAGCTT
4b4 726 CGGATTTTAGACTCATCACCAT
IVc (IV.3) 4c5 ATCCATTTCTCAGGAGTTAG
4c4 259 AGGAAATCGATGTCATTATAA
IVd (IV.4) 4d3 AATTCACCCGTACCTGAGAA
4d4 1,242 AGAATGTGGTTATAAGATAGCTA
(3) Multilocus sequence typing (MLST) [27]
carbamate kinase (arcC) arcC-Up TTGATTCACCAGCGCGTATTGTC
arcC-Dn 456 AGGTATCTGCTTCAATCAGCG4 International Journal of Pediatrics
Table 1: Continued.
Gene Primer name Size of product (bp) Primer sequence (5  →3 ) Reference
Shikimate dehydrogenase (aroE) aroE-Up ATCGGAAATCCTATTTCACATTC
aroE-Dn 456 GGTGTTGTATTAATAACGATATC
Glycerol kinase (glpF) glpF-Up CTAGGAACTGCAATCTTAATCC
glpF-Dn 465 TGGTAAAATCGCATGTCCAATTC
Guanylate kinase (gmk) gmk-Up ATCGTTTTATCGGGACCATC
gmk-Dn 429 TCATTAACTACAACGTAATCGTA
Phosphate acetyltransferase (pta) pta-Up GTTAAAATCGTATTACCTGAAGG
pta-Dn 474 GACCCTTTTGTTGAAAAGCTTAA
Triosephosphate isomerase (tpi) tpi-Up TCGTTCATTCTGAACGTCGTGAA
tpi-Dn 402 TTTGCACCTTCTAACAATTGTAC
Acetyl coenzyme A acetyltransferase (yqiL) yqiL-Up CAGCATACAGGACACCTATTGGC
yqiL-Dn 516 CGTTGAGGAATCGATACTGGAAC
Table 2: Age distribution in the 136 patients.
Age (years) MSSA MRSA Total
11 3 2 1 5
1–<21 9 2 2 1
2–<31 6 5 2 1
3–<41 6 2 1 8
4–<51 5 1 1 6
5–<61 7 0 1 7
6–<71 5 2 1 7
7–<12 11 0 11
Total 122 14 136
was no strain carrying both eta and etb genes. The MRSA
strains belonging to ST5 and ST8 were both etagene- and etb
gene-negative.
Antimicrobial susceptibilities of the MRSA and MSSA
strains to 12 antimicrobial agents are summarized in Table 4.
TheMICsof12antimicrobialagentsfor14individualMRSA
strains are shown in Table 5. β-Lactamase was produced
by 99 (72.8%) of the 136 S. aureus isolates. Of the 122
MSSA isolates, 85 (69.7%) were β-lactamase producers. All
MRSAisolateswereβ-lactamase-positive.MRSAstrainswere
highly resistant to CCL, CDTR, and CLDM. GM- and
CAM-resistant strains were frequently found in both MRSA
and MSSA. MINO, NDFX, FA and VCM had signiﬁcant
antimicrobial activity against the S. aureus isolates. The
ST5 MRSA strain exhibited resistance to multiple drugs,
including MINO and NDFX.
4. Discussion
The rate of CA-MRSA in patients with impetigo has been
increasing in Japan. In this study, only 10.3% of the S.
aureus isolates from patients with impetigo in Hokkaido,
the northernmost island of Japan, were MRSA. The ratio
of MRSA strains in Hokkaido is lower than those in other
r e g i o n si nr e c e n ts t u d i e s[ 21–24]. This ratio of CA-MRSA
in patients with impetigo in Hokkaido is similar to that
in healthy children previously reported in Japan [17, 18].
However, further continuous surveillance is needed to clarify
whether the low ratio of CA-MRSA in Hokkaido is true or
due to biases.
HA-MRSA strains usually carry large SCCmec type I, II,
or III and are usually multidrug resistant. On the other hand,
CA-MRSAstrainsusuallycarrysmallerSCCmec typeIVorV
and are usually more susceptible to non-β-lactam antibiotics
[11, 34]. In previous studies, SCCmec type IV MRSA
strains have been predominantly isolated from patients with
impetigo [22, 35, 36]. Noguchi et al. reported that 98.7%
of the MRSA strains isolated from patients with impetigo
and staphylococcal scalded skin syndrome between 1999 and
2004 in Japan had type IV SCCmec [35]. Takizawa et al.
reported that all of the characterized MRSA strains isolated
from patients with impetigo in 2003 and 2004 also had type
IV SCCmec [22]. Nakaminami et al. examined MRSA strains
isolated from patients with impetigo in Japan in 2006 and
reported that all isolates with SCCmec were classiﬁed into
type IV (92.8%) and V (7.2%) [36]. MRSA strains isolated
from children with impetigo in China from 2003 to 2007
were classiﬁed into type IV (54.5%), type V (18.2%), and VI
(9.1%) [37].
However, in very recent studies, MRSA strains isolated
from patients with impetigo had diverse SCCmec types, and
SCCmec type IIb has been increasing [23, 24]. Type IIb
SCCmec wasﬁrstidentiﬁedfromMRSAstrainsisolatedfrom
healthy Japanese children [17]. Hisata et al. characterized
17 MRSA strains isolated from patients with impetigo at
a Japanese hospital from June through August 2002. They
found that the 17 MRSA strains carried diverse types of
SCCmec: type II (IIb: 4 strains; unknown subtype: 2 strains),
type IV (7 strains), and type V (4 strains) [23]. Shi et al.
reported that among 26 MRSA strains isolated from patients
with impetigo, 57.7% carried type IIa SCCmec element
and 42.3% carried type IV SCCmec element [24]. In the
present study, the MRSA strains isolated from patients with
impetigo also had diverse SCCmec types, and SCCmec type
II, including type IIb and IINT, was the predominant type
among the CA-MRSA strains.International Journal of Pediatrics 5
Table 3: Molecular characterization of 14 MRSA strains isolated from patients with impetigo.
Strain Age
SCCmec typing MLST Presence of exotoxin genes
SCCmec type ccr mec ST CC Allelic proﬁle lukS-PV-lukF-PV tst eta etb
T-11 1 yr IIb 2 A 2117 89 1-310-28-18-18-33-50 −− − +
T-33 6 yrs 4 mos IVa 2 B 91 89 1-26-28-18-18-54-50 −− − +
T-55 2 yrs 6 mos NT NT A 89 89 1-26-28-18-18-33-50 −− − +
T-64 2 yra 6 mos IINT 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-71 6 yrs 6 mos IIb 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-79 3 yrs 10 mos IVa 2 B 91 89 1-26-28-18-18-54-50 −− − +
T-83 3 yrs 11 mos IINT 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-114 2 yrs 3 mos NT NT A 89 89 1-26-28-18-18-33-50 −− − +
T-119 2 yrs 2 mos NT NT A 5 5 1-4-1-4-12-1-10 − + −−
T-125 4 yrs V 5 C2 121 121 6-5-6-2-7-14-5 −− + −
T-132 19 ds IINT 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-137 1 yr 1 mo IIb 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-139 10 ds IINT 2 A 89 89 1-26-28-18-18-33-50 −− − +
T-144 2 yrs 1 mo IVa 2 B 8 8 3-3-1-1-4-4-3 − + −−
NT: nontypeable.
Table 4: Comparison of antimicrobial susceptibilities of MRSA and MSSA.
Antimicrobial
agent
Resistance
breakpoint
(μg/mL)
MSSA (n = 122) MRSA (n = 14)
Range (μg/mL) MIC90
(μg/mL)
Resistance
(%)
Range
(μg/mL)
MIC90
(μg/mL)
Resistance
(%)
MPIPC 4 2 20 4 – >8 >8 100
ABPC 0.5  0.12 516 16 71.3 4–>16 >16 100
CCL 16 1–16 4 1.6 4–>16 >16 92.9
CDTR 2∗ 0.5 –2 1 0.8 2–>16 >16 100
CAM 4  0.12516 >16 67.2 >16 >16 100
CLDM 1 0.125–0.25 0.25 0 0.125–>16 >16 71.4
FOM 8∗∗ 0.25–>16 16 20.5 1–>16 8 14.3
MINO 8 0.125–0.25 0.125 0 0.125–16 0.25 7.1
GM 8 0.25–>16 >16 54.1 1–>16 >16 92.9
VCM 4 0.5–1 1 0 1-2 1 0
NDFX 4∗∗ 0.125–2 0.125 0 0.125–>16 0.125 7.1
FA 2∗∗ 0.125–>16 0.5 0.82 0.125–1 0.5 0
The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI).
Susceptibility to antimicrobial drugs for which breakpoints are not determined by CLSI was according to the interpretation criteria of the Japan Society for
Chemotherapy (∗) or deﬁned in this study (∗∗).
The role of PVL in the pathogenesis of staphylococcal
infections is controversial [38]. However, PVL is responsible
at least in part for the increased virulence of CA-MRSA.
PVL-positive S. aureus strains are more frequently associated
with cellulitis and abscesses than with impetigo [39–41]. In
this study, none of the MRSA isolates carried the PVL gene.
Although highly virulent CA-MRSA strains carrying PVL
genes are known to prevail in the world, the prevalence of
PVL-positive strains in Japan is not high [15, 17, 18, 23, 25].
There are three serological forms of ET, ETA, ETB, and ETD,
which are linked to human impetigo [19]. The eta gene,
encoding ETA, is located on a chromosome, whereas the
etb gene, encoding ETB, is present on a plasmid. The eta
and etb genes are generally found in S. aureus isolated from
patients with impetigo. The etb gene is predominantly found
in MRSAstrainswith mecA.In this context, our data support
previous data [21, 23, 24, 35, 36].
MLST is an excellent tool for investigating clonal evo-
lution of MRSA. Six STs (ST5, ST8, ST89, ST91, ST121,
and ST2117) were identiﬁed, and they were classiﬁed into
four CCs (CC5, CC8, CC89, and CC121) in the present
study. PVL-negative CA-MRSA strains, which belong to
ST89 and ST91, have been associated with impetigo in
Japanese children [22–24]. In this study, the most common
ST in MRSA strains was also ST89 (57.1%), followed by
ST91 (14.3%). ST89 and ST91 both belonged to the same6 International Journal of Pediatrics
Table 5: Antimicrobial susceptibilities of 14 MRSA strains.
Strain MIC (μg/mL) of antimicrobial agents
MPIPC ABPC CCL CDTR CAM CLDM FOM MINO GM VCM NDFX FA
T-11 >8 >16 >16 >16 >16 >16 1 0.125 >16 2 0.125 0.25
T-33 >81 6 >16 4 >16 >16 2 0.125 >16 1 0.125 0.25
T-55 >81 6 >16 8 >16 >16 4 0.25 >16 1 0.125 0.25
T-64 >8 >16 >16 >16 >16 >16 2 0.125 >16 1 0.125 0.25
T-71 >81 6 1 64 >16 >16 2 0.125 >16 1 0.125 0.125
T-79 >81 6 >16 4 >16 0.125 4 0.125 >16 1 0.125 0.25
T-83 >81 6 >16 4 >16 >16 2 0.25 >16 1 0.125 0.125
T-114 >81 6 >16 16 >16 >16 1 0.125 >16 1 0.125 0.25
T-119 >8 >16 >16 >16 >16 0.125 >16 16 >16 1 >16 0.5
T-125 4 4 4 2 >16 0.25 4 0.125 >16 1 0.125 0.25
T-132 >81 6 >16 16 >16 >16 2 0.125 >16 1 0.125 0.125
T-137 >8 >16 >16 >16 >16 >16 2 0.125 >16 1 0.125 1
T-139 >81 6 >16 16 >16 >16 2 0.125 >16 1 0.125 0.25
T-144 >81 6 >16 16 >16 0.125 8 0.125 1 1 0.125 0.25
CC89. We found that 11 of the 14 MRSA strains belonged to
CC89 and carried diverse SCCmec types, IIb, IINT,I v a ,a n d
NT. Although one strain belonging to ST5, which has been
commonly identiﬁed in HA-MRSA with type II SCCmec,
was found in our MRSA isolates, it carried a nontypeable
SCCmec element. The class of mec gene complex in the strain
was class A, indicating that its SCCmec type should be a type
other than type I, IV, V, VI, or VII [42]. In a previous study
by Hisata et al. ST5 MRSA with SCCmec type IIa, which was
indistinguishable from HA-MRSA strains (New York/Japan
clone [5]) in Japan, accounted for 22.7% of MRSA strains
isolated from healthy children [17]. Our ST5 MRSA strain
was resistant to multiple drugs, including MINO and NDFX.
Although ST8 MRSA strain with SCCmec type IVa [22, 43]
and ST121 MRSA strain with SCCmec type V [44, 45]h a v e
been identiﬁed in CA-MRSA associated with impetigo, our
MRSA strains with the same phenotypes did not carry PVL.
It is generally accepted that bacterial resistance to
antimicrobial agents parallels the frequency of use of the
agents. Unlike HA-MRSA, CA-MRSA is generally susceptible
to non-β-lactam antibiotics, such as aminoglycosides, tetra-
cyclines, and ﬂuoroquinolones. However, S. aureus isolates
from patients with impetigo were highly resistant to GM
and CAM, reﬂecting frequent usage of GM ointment for
the treatment of skin infections including impetigo and
frequent usage of CAM for respiratory infection in Japan
[20, 21, 35, 36].
5. Conclusions
This study and a previous study indicated that PVL-negative
CC89 strain with a marked divergence in SCCmec types
predominated in Japanese communities, suggesting that it
mightbeaJapanesedomesticCA-MRSAclone.Theexistence
of multiple types of SCCmec elements suggested that MRSA
strains might be emerging locally in the community under
the selective pressure of antibiotics. Furthermore, SCCmec
II CA-MRSA may at least partially be beginning to replace
SCCmec IVa CA-MRSA. Continuous monitoring of MRSA
epidemiology using MLST and SCCmec typing and drug
resistance trends would show change in the clonal distri-
bution of MRSA, which may be crucial for the eﬀective
management of impetigo.
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